Skip to main content
RACC logo

RACC · Research Alliance Corp III

Track RACC — free
$10.11 +0.04 (+0.40%)
Market Cap
$91.62M
Shares
9.10M
Volume · Nov 19 41.24K Avg daily vol (3M) 86.84K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.07 Open$10.12 Day$10.05–10.13 Available close range$10.07–29.30 Avg vol 30d57K Short int8K · 0.1% of shares · 1.0d Short vol0% DataMay 2026–Nov 2026 Filing10-Q · Nov 16

The closing range uses available history since May 20, 2026; less than a full year is stored.

Latest documents

2026
Nov 16
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Oak Hill Bio combination targets fourth quarter of 2026 close

Research Alliance Corporation III’s Oak Hill Bio combination is expected to close in the fourth quarter of 2026, supported by $55,000,000 of PIPE financing. Disclosure controls were ineffective as of September 30, 2026 due to a material weakness.

Read from the MD&A section
5 source passages
References to the “Company”, “us”, “our”, or “we” refer to Research Alliance Corporation III. However, in connection with the proposed business combination with OHB Pediatrics Ltd. (“Oak Hill Bio”), we filed a registration statement on Form S-4 (File No. 333-298537), which was declared effective by the Securities and Exchange Commission on November 4, 2026, and a related definitive proxy statement/prospectus pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on November 4, 2026 (the “Proxy Statement/Prospectus”). The OHBP Business Combination is expected to close in the fourth quarter of 2026, following the receipt of the requisite approvals of the Company’s shareholders and the fulfillment of other customary closing conditions. Pursuant to the Subscription Agreements, the PIPE Investors agreed to subscribe for and purchase, and the Company agreed to issue and sell to the PIPE Investors, on the date the Closing occurs (the “Closing Date”), (a) shares of New OHB Common Stock at $10.00 per share and/or (b) pre-funded warrants to purchase shares of New OHB Common Stock (the “Pre-Funded Warrants”), each to purchase one share of New OHB Common Stock, with a per share exercise price equal to $0.0001, at a purchase price per Pre-Funded Warrant equal to $10.00 less the exercise price (collectively, the “PIPE Financing”), for aggregate gross proceeds of $55,000,000. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2026, our disclosure controls and procedures were not effective as we experienced difficulty in ensuring that the accounting for our accounts payable and accrued expenses is accurate and complete, including proper classification of the related expenses to deferred offering costs or operating expenses which we experienced and reported as a material weakness. Open the document at this passage
Oct 30
Registration statement S-4/A
Shareholders to Vote on $160,000,000 Oak Hill Bio Merger

Research Alliance Corporation III seeks shareholder approval at its November 24, 2026 meeting for a business combination with Oak Hill Bio, which has a $160,000,000 base equity value, plus a $55,000,000 PIPE financing.

Read from the first part of this long document
4 source passages
The extraordinary general meeting will be conducted via live webcast at 10:00 a.m., Eastern Time, on November 24, 2026, at the offices of Cooley LLP the Oak Hill Bio Shareholders will receive an aggregate of 16,000,000 shares of New OHB Common Stock in the Transactions upon the exchange of Oak Hill Bio Shares, based on the Base Equity Value of $160,000,000 divided by $10.00 per share. The aggregate gross proceeds to be received by RACC in connection with the PIPE Financing will be $55,000,000. Open the document at this passage
Sep 28
Registration statement S-4/A
Registration statement

Research Alliance Corporation III agreed to acquire OHB Pediatrics Ltd., issue 16,000,000 shares to its shareholders, and raise $55,000,000 through a PIPE financing; the combined company will move to Delaware and become Oak Hill Bio Inc.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$183,405
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Limited Sentiment Neutral Fundamentals Limited Quant / Vol High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 50-day avg −4%
below
RSI (14) 27
oversold
MACD trend Positive
52-week position 0%
near low
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-22% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.08% of shares out · ▼ -12.3% MoM · 1.0 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
18 holders — 13F breadth
Squeeze score 35
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
High
Volatility 93%
annualized · 1-yr
Max drawdown −66%
past year
ATR 1.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−4% Neutral
RSI (14)
27 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-22% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.08% of shares out · ▼ -12.3% MoM · 1.0 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
18 holders — 13F breadth
Price context
position in its available closing range
Range low $10 Now $10 · 0% Range high $29
vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Shell Companies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RACC
Research Alliance Corp III
this stock
$91.62M — — — 0.1%
VYLR
Vylor Inc.
$46.59B — — — 2.1%
CLUS
Cluster Group Holdings Ltd Co
$8.00B — — — —
DMII
Drugs Made In America Acquisition II Corp.
$651.65M +3.3% — — 0.2%
EVAC
EQV Ventures Acquisition Corp. II
$606.10M +3.4% — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
18
% held
78.7%
Net QoQ
-267.4K sh
Top holder
Nantahala Capital Managem…
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
7.6K
Days to cover
1.0d
Change
-1.1K sh
View
Short Volume
Short vol %
0%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
163
Value
$1.6K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
67.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 16, 2026
This year
12

Research Alliance Corporation III’s Oak Hill Bio combination is expected to close in the fourth quarter of 2026, supported by $55,000,000 of PIPE financing. Disclosure controls were ineffective as of September 30, 2026 due to a material weakness.

View
Earnings & Events
Investor Relations
Latest news
Oak Hill Bio and Research Allianc…
Published
Jul 27, 2026
View

Performance

5D 20D 120D MTD YTD
RACC -0.8% -1.0% — -0.8% —
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +3.1% +4.6% — +2.6% —
Key facts CIK 2118032 CUSIP G75226103 13F (30d) 18 filings 18 filers